PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31746350-0	2020	Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.	salinomycin	0-11	ret proto-oncogene	Homo sapiens	42-45	
31746350-2	2020	The present study reports the first preclinical characterization of salinomycin and selected analogs as potent RET transcriptional inhibitors.	salinomycin	68-79	ret proto-oncogene	Homo sapiens	111-114	
31746350-3	2020	Reverse transcription-PCR and immunoblotting revealed that salinomycin profoundly decreased RET expression in the TT human MTC cell line by inhibiting RET transcription.	salinomycin	59-70	ret proto-oncogene	Homo sapiens	92-95	
31746350-3	2020	Reverse transcription-PCR and immunoblotting revealed that salinomycin profoundly decreased RET expression in the TT human MTC cell line by inhibiting RET transcription.	salinomycin	59-70	ret proto-oncogene	Homo sapiens	151-154	
31746350-4	2020	Moreover, salinomycin resulted in remarkable anti-proliferative activity against MTC that is driven by RET (gain of function mutation) by selectively inhibiting the intracellular PI3K/Akt/mTOR signaling pathway.	salinomycin	10-21	ret proto-oncogene	Homo sapiens	103-106	
31746350-7	2020	Some of the salinomycin derivatives showed the ability to reduce RET expression where others fail to alter RET expression.	salinomycin	12-23	ret proto-oncogene	Homo sapiens	65-68	
31746350-8	2020	These results suggest that the RET-suppressing effect of salinomycin may be largely attributed to disruption of the Wnt pathway, presumably through interference with the ternary LRP6-Frizzled-Wnt complex.	salinomycin	57-68	ret proto-oncogene	Homo sapiens	31-34